Insight journal

Life Science Intelligence for Deal Makers
Welcome to Insight Journal, where you can explore a series of articles and posts written by CP analysts that cover recent partnering trends, significant deals, company partnering strategies and therapy forecasts.

These articles have been written not only to give you insights but advice into popular issues such as the top therapeutic areas and companies to partner with, as well as providing opinion on the latest deal talk.

Insight journal is regularly updated with breaking news as it happens and rumours of potential deals. 

CP Insight: Login | More details | Subscription options

Featured insights

Isis Pharmaceuticals: Partnering activity 2009-2014

September 15, 2014 : cardiovascular, oncology, pharmaceuticals

Isis Pharmaceuticals, a leader in antisense drug discovery, has emerged as a top 50 big biotech company with its business strategy. more »

Jazz Pharmaceuticals – A new entry into the top 50 biotech of 2014

September 8, 2014 : biopharmaceutical, leukemia, narcolepsy, oncology

Headquartered in Dublin, Ireland Jazz Pharmaceuticals is a specialty biopharmaceuticals company that has undergone significant growth in recent years. Jazz Pharmaceuticals is focused upon delivering products for cataplexy, narcolepsy, oncology/leukemia, chronic pain and non-opioid schizophrenia.   more »

Orphan diseases partnering: A lucrative step for drug makers

September 2, 2014 : M&A, orphan diseases, partnering

By Shamini Thiagarajan

Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases. more »

Isis Pharmaceuticals: So many partnerships, so little time

September 2, 2014 : antisense, drug discovery, oncology, RNA

Isis Pharmaceuticals is an antisense drug discovery technology company developing therapies for a number of serious diseases. more »

Jazz Pharmaceuticals: M&A activity 2009-2014

September 1, 2014 : narcolepsy, oncology, pharmaceuticals

Jazz Pharmaceuticals, listed as a new big biotech entrant in 2014, has announced 3 M&A deals since 2009, with the lead deals being the acquisitions of Gentium and merger with Azur Pharma. more »


Company insights

Therapy insights

Technology insights

Deals and alliances insights

Dealtalk Insights

Print Friendly
RSS Feed Linked In Twitter

Latest Tweets